另外，公司管线2.0重磅产品CS5001（ROR1 ADC）全球多中心1b期临床试验顺利完成首例患者入组。临床数据显示，CS5001作为单药治疗侵袭性和惰性晚期淋巴瘤的客观缓解率（ORR）高于同类竞品，具有快速上市注册及冲击一线联合治疗格局的潜力。据悉，CS5001全球多中心试验在美国、澳大利亚和中国同步进行，目前已推进至1b期进行剂量优化，后续潜在扩展为II期单臂注册研究。CSTONE PHARMA-B (02616) rose nearly 7%. As of the time of this report, it has increased by 6.96%, priced at 2.46 Hong Kong dollars, with a trading volume of 11.9243 million Hong Kong dollars.
According to Zhizhong Finance APP, CSTONE PHARMA-B (02616) rose nearly 7%, and as of the time of publication, it rose 6.96% to 2.46 HKD, with a transaction amount of 11.9243 million HKD.
In news, CSTONE PHARMA previously announced that its pipeline's 2.0 heavyweight product CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody) has submitted a clinical trial application in Australia. This study has also been registered on the Clinicaltrials.gov website (registration number: NCT06741644) and made public. Preclinical data show that CS2009 has significantly superior anti-tumor activity compared to potential competitors and is expected to cover a wide range of tumors, including non-small cell lung cancer, ovarian cancer, renal cell carcinoma, cervical cancer, liver cancer, and gastric cancer, making it a first-in-class/ best-in-class next-generation tumor immune scaffold product.
Additionally, the global multi-center phase 1b clinical trial of the company's pipeline's 2.0 heavyweight product CS5001 (ROR1 ADC) has successfully completed the recruitment of its first patient. Clinical data show that CS5001 as a monotherapy for aggressive and indolent advanced lymphoma has an objective response rate (ORR) higher than comparable products, with the potential for rapid market registration and impact on first-line combination treatment patterns. It is reported that the global multi-center trial of CS5001 is being conducted simultaneously in the USA, Australia, and China, currently advancing to phase 1b for dose optimization, with potential future expansion to a phase II single-arm registration study.
